【导读】肿瘤免疫微环境与肝细胞癌（HCC）的恶性行为密切相关。然而，HCC中B细胞的免疫功能和调节机制尚不清楚。10月18日，复旦大学研究团队在期刊《Advanced Science》上发表了研究论文，题为“Increased PRP19 in ...

2024年10月29日，葛兰素史克（GSK）宣布，与恩沐生物（Chimagen Biosciences）达成协议，GSK以3亿美元的预付款从恩沐生物收购CMG1A46，获得CMG1A46的全部全球权利。

PHILADELPHIA, PA — Interius BioTherapeutics has taken a significant step forward with the dosing of its first participant in ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However, GSK has ...